When the Trump administration announced earlier this year that it would not finalize a provision proposed by the Biden administration to expand Medicare and Medicaid coverage of GLP-1s, many advocates responded with deep disappointment.

But this month, the Trump administration unveiled its own efforts to expand access to the popular weight loss drugs, announcing an agreement with GLP-1 manufacturers Eli Lilly and Novo Nordisk. The agreement will allow patients to access GLP-1s for significantly cheaper prices through TrumpRx, a government-run direct-to-consumer drug platform. It also reduces prices under Medicare and Medicaid, and enables Medicare to cover GLP-1s for obesity for the first time.

Aside from striking a deal with the Trump administration, Eli Lilly is also charting a new

See Full Page